Skip to content

Breast Cancer

EU Focus Meeting 2026


📍 SANA Malhoa Hotel, Av. José Malhoa 8, 1099-089 Lisbon,  Portugal

🗓️ 25-26 September, 2026


Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the Breast Cancer Focus Meeting 2026, to be held at on September 25 - 26, 2026.

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing Breast Cancer research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

 

 

Chairs of Breast Cancer Focus Meeting 2026:

Javier-Cortes

Javier Cortés, MD
nternational Breast Cancer Center
(IBCC), Barcelona, and IOB Madrid,
Spain

Virginia-Kaklamani

Virginia  Kaklamani, MD
UT Health, San Antonio, TX


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
cristina.anton@md-education.com

Agenda & Faculty

July 9, 2026 | Day 1  

01:00 PM
Registration Opens

Session I: TBD
Moderated by:

TBD
KOL TBD


02:00 PM
Updates on CML
Hagop-Kantarjian
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
02:15 PM
Updates on CLL
Susan-OBrien
Susan O’Brien, MD
University of California, Irvine Medical Center, Los Angeles, CA
02:30 PM
Updates on Low Risk MDS
Rami-Komrokji
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL
02:45 PM
Panel Discussion
03:15 PM
Coffee Break

Session II: TBD
Moderated by:

TBD
KOL TBD


03:35 AM
Updates on High Risk MDS
Guillermo-GarciaManero
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX
03:50 AM
Updates on BPDCN
Naveen-Pemmaraju
Naveen Pemmaraju, MD
MD Anderson Cancer Center, Houston, TX
04:05 AM
Panel Discussion
04:35 PM
Adjourn

July 10, 2026 | Day 2  

08:00 AM
Registration Opens

Session III: TBD
Moderated by:

TBD
KOL TBD


09:00 AM
Molecular Risk Stratification in ALL
Charles-Mullighan
Charles Mullighan, MD
St. Jude Children’s Research Hospital, Memphis, TN
09:15 AM
How I Treat Ph-Positive ALL
Elias-Jabbour
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
09:30 AM
MRD in Ph-positive ALL BCR:ABL1 vs NGS for IgR
Nicholas-Short
Nicholas Short, MD
MD Anderson Cancer Center, Houston, TX
09:45 AM
Older ALL
Matthew-Wieduwilt
Matthew Wieduwilt, MD
Wake Forest University School of Medicine, Winston-Salem, NC
10:00 AM
Panel Discussion
10:30 AM
Coffee Break & Networking

Session IV: TBD
Moderated by:

TBD
KOL TBD

10:50 AM
Genetic and Molecular Diagnostics in AML
Sanam-Loghavi
Sanam Loghavi, MD
MD Anderson Cancer Center, Houston, TX
11:05 AM
Genomic Strategies to Guide the Choice of Intensive Treatment Strategies in NonFLT3m AML
Eunice-Wang
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY
11:20 AM
Frontline Treatment of FLT3-ITD Mutated AML – Where are we Headed
Alexander-Perl
Alexander Perl, MD
Perelman School of Medicine, Philadelphia, PA
11:35 AM
Optimizing Maintenance Approaches in Non-Transplanted Patients With AML
Tapan-Kadia
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX
11:50 AM
Optimizing Post-Transplant Maintenance Approaches and the ACT Platform Successes in SCT
Charlie-Craddock
Charlie Craddock, MD
Queen Elizabeth Hospital, Birmingham, UK
12:05 PM
Panel Discussion
12:35 PM
Industry Supported Independent Expert Discussion
01:20 PM

Lunch Break

Session V: TBD
Moderated by:

TBD
KOL TBD

 

02:10 PM
Management of ALL: Closing the Gap Between Centers of Excellence and Underserved Communities
Lori-Muffly
Lori Muffly, MD
Stanford Medicine, CA
02:25 PM
MRD Eradication and When Allogeneic Transplant is Still Needed
Aaron-Logan
Aaron Logan, MD
UCSF Helen Diller Family Comprehensive Cancer Center, CA
02:40 PM
How Much Chemotherapy is Still Needed in Newly Diagnosed Adults With ALL
Hagop-Kantarjian
Hagop Kantarjian, MD
MD Anderson Cancer Center, Houston, TX
02:55 PM
Questions Re Pediatric Regimens: Less Toxic, Equally Effective?
Wendy-Stock
Wendy Stock, MD
The University of Chicago Medicine, Chicago, IL
03:10 PM
Panel Discussion
03:40 PM
Coffee Break & Networking

Session VI: TBD
Moderated by:

TBD
KOL TBD

 

04:00 PM
AZA+VEN for all – or Not Really?
Amir-Fathi
Amir Fathi, MD
Massachusetts General Hospital, Boston, MA
04:15 PM
Triplets in AML: Are We There Yet and If So for Which Ones Are We Really There?
Naval-Daver
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX
04:30 PM
How do I use IDH Inhibitors in Frontline and R/R AML AML
Courtney-Dinardo
Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX
04:45 PM
Optimizing Treatment of R/R FLT3-Mutated AML, Emerging Mechanisms of Resistance and Potential Approaches to Overcome
Jessica-Altman
Jessica Altman, MD
Northwestern University Feinberg School of Medicine, Chicago, IL
05:00 PM
Optimizing Measurement of MRD in AML and How Should We Use MRD in Guiding the Treatment of AML
Christopher-Hourigan
Christopher Hourigan, MD
Virginia Tech FBRI Cancer Research Center, Blacksburg, VA
05:15 PM
Panel Discussion
05:45 PM
Special Lecture: FDA Perspectives on Endpoints in AML and Applications of MRD for AML Drug Development
Kelly-Norsworthy
Kelly Norsworthy, MD
Johns Hopkins Medicine, Baltimore, MD
05:25 PM
Question & Adjourn

July 10, 2026 | Day 2  

08:00 AM
Registration Opens

Session VII: TBD
Moderated by:

TBD
KOL TBD

 

09:00 AM
Novel Agents in R/R ALL: SQ Blina
Elias-Jabbour
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX
09:15 AM
Other Bispecifics and ADC
Ibrahim-Aldoss
Ibrahim Aldoss, MD
City of Hope Comprehensive Cancer Center, Duarte, CA
09:30 AM
How to Optimize Outcomes Post CAR T
Bijal-Shah
Bijal Shah, MD
Moffitt Cancer Center, Tampa, FL
09:45 AM
Optimizing Maintenance Approaches in Non-Transplanted Patients With AML
Jae-Park
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY
10:00 AM
Optimizing Post-Transplant Maintenance Approaches and the ACT Platform Successes in SCT
Nitin-Jain
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX
10:15 AM
Panel Discussion
10:45 AM
Coffee Break & Networking

Session VIII: TBD
Moderated by:

TBD
KOL TBD

 

11:05 AM
Frontline Fit NPM1 Mutated AML: What Are the Current Data and Where Do We See This Evolving in the Near Future
Amer-Zeidan
Amer Zeidan, MD
Yale School of Medicine, Connecticut
11:20 AM
Menin Inhibitors in R/R AML: Updates on Single Agent Efficacy, Safety, Resistance and Role of Second Generation Menin Inhibitors
Ghayas-Issa
Ghayas Issa, MD
MD Anderson Cancer Center, Houston, TX
11:35 AM
Moving Beyond Single-Agent Menin Inhibitors: Emerging Data and Optimization of Menin Inhibitor Combos
Joshua-Zeidner
Joshua Zeidner, MD
UNC School of Medicine, Chapel Hill, NC
11:50 AM
Panel Discussion
12:20 PM
Industry Supported Independent Expert Discussion
01:05 AM
Lunch & Networking

Session IX: TBD
Moderated by:

TBD
KOL TBD

 

01:55 PM
TP53 Mutated ALL and ALL With Myeloid Mutations
Caner-Saygin
Caner Saygin, MD
The University of Chicago Medicine, Chicago, IL
02:10 PM
BH3 Mimetics in ALL
Daniel-Deangelo
Daniel J. DeAngelo, MD
Dana-Farber Cancer Institute, Boston, MA
02:25 PM
CAR T-cells of T-ALL
Armin-Ghobadi
Armin Ghobadi, MD
Washington University School of Medicine, St. Louis, MO
02:40 PM
MPAL Management
Jayastu-Senapati
Jayastu Senapati, MD
MD Anderson Cancer Center, Houston, TX
02:55 PM
Panel Discussion
03:25 PM
Coffee Break & Networking

Session X: TBD
Moderated by:

TBD
KOL TBD

 

04:05 PM
Developing CARTs in AML: Current Status, Challenges, Emerging Constructs and Future Directions
Saar-Gill
Saar Gill, MD
Penn Medicine, Philadelphia, PAX
04:20 PM
CD33 and CD123 ADCs in AML: From GO to CD123 – Has the Path Been Paved?
Farhad-Ravandi
Farhad Ravandi, MD
MD Anderson Cancer Center, Houston, TX
04:35 PM
Optimal Dose of VEN in Frontline HMAVEN and Implications for Future Triplets/Combos
Uma-Borate
Uma Borate, MD
The Ohio State University, Ohio
04:50 PM
Panel Discussion & Take-home Points
05:20 PM
Adjourn

Cristina Anton
Project Manager

How long has Cristina Anton been in the business?

Cristina Anton has been with MD Education since 2022

About Cristina Anton

As a Senior Project Manager at MD Education’s Wigan office since 2022, I organize international medical conferences with a focus on breast cancer and inflammatory bowel disease (IBD). Originally from Romania, I have been based in the UK since 2015. My diverse background across sectors helps me deliver high-quality, impactful educational programs. I’m committed to excellence and continuous growth.

Cristina-Anton